Clinical trials: Immune System Tolerance
Acute Respiratory Distress Syndrome
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)…
- Trial name
- NCT05983627
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Healthy Volunteers
The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers
A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of jaktinib.
- Trial name
- NCT03314402
- Testing
- Jaktinib Dihydrochloride Monohydrate
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Gastrointestinal Tolerance
A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber
The purpose of this study is to determine the upper tolerable limit of Sugars from Fiber
- Trial name
- NCT05051202
- Testing
- Sugars from Fiber, Resistant Maltodextrin
- Where
- Ireland
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cambridge Glycoscience
NSCLC Stage IIIB, NSCLC Stage IV
Phase I Study of SPH1188-11 in NSCLC
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment.
- Trial name
- SPH1188-11 (NCT03231475)
- Testing
- SPH1188-11
- Where
- China
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Growth
Preterm Infants Fed a Human Milk Fortifier
This is a double-blind, randomized, multi-center, controlled, parallel study to evaluate the growth and tolerance of preterm infants fed human milk fortifier (HMF).
- Trial name
- NCT05551975
- Testing
- Control Product, Experimental Product 1, Experimental Product 2
- Where
- 14 sites in United States
- Volunteers
- 321 people
- Sponsor
- Abbott Nutrition
Healthy
A Study of a Whole-Body Balm on Newborn Babies
The purpose of this study is to evaluate the skin tolerance, instrumental efficacy, and perceived product efficacy of a whole-body balm on newborns (0-28 days old).
- Trial name
- NCT05786209
- Testing
- Whole-body Balm
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Cachexia, Chronic Obstructive Pulmonary Disease
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and…
- Conditions
- Cachexia, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure
- Trial name
- NCT00852020
- Testing
- oral nutrition supplement, food for special medical purposes
- Where
- 4 sites in Germany, Poland
- Volunteers
- 60 people
- Sponsor
- Fresenius Kabi
Hypersensitive, Reactive and Intolerant Skin
IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Balm)
The aim of this study is to assess the dermatological and ophthalmological tolerance of the investigational product Baume visage / Face balm RV4942A - RY1985 after 21 days of twice daily use on the study areas, under normal…
- Conditions
- Hypersensitive, Reactive and Intolerant Skin, Redness-prone Skin, Stinger Subjects
- Trial name
- NCT05171556
- Testing
- Cosmetic product
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Sickle Cell Disease
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
This is a pilot study of daily dosing of NUV001 as a dietary supplement in 12 sickle cell disease patients with 3 months of follow-up plus 1 month after supplementation.The present study is designed to evaluate, first, the safety…
- Trial name
- NCT05789355
- Testing
- NUV001
- Where
- France
- Volunteers
- 12 people
- Sponsor
- LGD
Tolerance
An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide
This study evaluates the safety and tolerability of three different doses (5 g, 10 g and 20 g) of a collagen powder in healthy adults over a 12-week period.
- Trial name
- NCT06232460
- Testing
- H80
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Healthy Term Infants Solely Formula Fed
Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula
To compare the number of infants who discontinue from study formula due to formula intolerance as documented by the investigator. Hypothesize there will be no difference between formula groups.
- Trial name
- NCT00666120
- Testing
- Enfamil LIPIL with iron, Good Start Supreme with DHA and ARA
- Where
- 18 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Study of Three Doses of AZT-04 for Skin Appearance
Safety Study of AZT-04 for Cosmetic Use
Double Blind, Three Cohort, Placebo-controlled Trial to Assess Safety, Tolerance and Induced Bacterial Colony Counts of Three Ascending Doses of AZT-04 in Healthy Adult Volunteers
- Trial name
- NCT03820076
- Testing
- AZT-04
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Azitra Inc.
Acne Vulgaris
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl…
- Trial name
- NCT00926367
- Testing
- Clindamycin and benzoyl peroxide, benzoyl peroxide 2.5% and adapalene 0.1% gel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Stiefel, a GSK Company
Healthy Adult Volunteers
99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers
The objectives of this study are: To determine the safety and tolerability of a single dose of 99mTc-rhAnnexin V-128 administered as an intravenous bolus over 10-20 seconds.
- Trial name
- NCT02182609
- Testing
- Kit for the Preparation of 99mTc-rhAnnexin V-128
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Advanced Accelerator Applications
Advanced Cancer
A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics
To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02996838
- Testing
- TQ-B3234
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Vascular Diseases, Impaired Glucose Tolerance
Effects of Dietary Ingredients on Vascular Function
The main aim of the study is to investigate the effects of dietary ingredients (polyphenols and carotenoids) on vascular function during acute glucose load.
- Trial name
- NCT02158481
- Testing
- A capsule containing both polyphenols and carotenoids
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Unilever R&D
COVID-19 Pneumonia
Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
phase I study will evaluate the safety and tolerability of GEN2-Recombinant COVID-19 Vaccine (CHO cells) in healthy people aged 18 years and older.
- Trial name
- NCT05408312
- Testing
- Experimental Vaccine 1, Experimental Vaccine 2, Experimental Vaccine 3
- Where
- China
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Subjects in Need of a Human Milk Fortifier (HMF), Growth
Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants.
Preterm birth (birth before start of the 37th week of gestation) is a major determinant of neonatal morbidity and mortality and has long-term adverse consequences for health and neurodevelopment.
- Conditions
- Subjects in Need of a Human Milk Fortifier (HMF), Growth, Tolerance, Safety
- Trial name
- Renoir (NCT03315221)
- Testing
- Test product, Control product
- Where
- 15 sites in France, Germany and 2 more
- Volunteers
- 207 people
- Sponsor
- Nutricia Research
Growth, Tolerance
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT).
- Conditions
- Growth, Tolerance, Adverse Event, Disorder of Intestine
- Trial name
- NEHMO (NCT04055363)
- Testing
- HMO-supplemented infant formula
- Where
- 6 sites in Spain
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Keloid
Safety of Juvista When Administered Following Excision of Ear Lobe Keloids
This trial will assess the safety and efficacy of 500ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe.
- Trial name
- RN1001-0093 (NCT00710333)
- Testing
- Avotermin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Renovo